Lupin Ready To Spend $1 Billion On Europe Acquisitions, CEO Says
This article was originally published in PharmAsia News
Executive Summary
Lupin is willing to spend up to $1 billion acquiring generics drug makers in Europe, particularly makers of inhalants, injectables, skin products and biosimilars, said CEO Vinita Gupta in an interview.